![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PKIA |
Gene summary for PKIA |
![]() |
Gene information | Species | Human | Gene symbol | PKIA | Gene ID | 5569 |
Gene name | cAMP-dependent protein kinase inhibitor alpha | |
Gene Alias | PRKACN1 | |
Cytomap | 8q21.13 | |
Gene Type | protein-coding | GO ID | GO:0000086 | UniProtAcc | A0A024R7Y9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5569 | PKIA | male-WTA | Human | Thyroid | PTC | 4.51e-33 | 2.69e-01 | 0.1037 |
5569 | PKIA | PTC01 | Human | Thyroid | PTC | 1.02e-03 | -3.40e-02 | 0.1899 |
5569 | PKIA | PTC04 | Human | Thyroid | PTC | 4.76e-06 | -5.18e-02 | 0.1927 |
5569 | PKIA | PTC05 | Human | Thyroid | PTC | 1.83e-08 | 5.81e-01 | 0.2065 |
5569 | PKIA | PTC06 | Human | Thyroid | PTC | 2.00e-23 | 6.74e-01 | 0.2057 |
5569 | PKIA | PTC07 | Human | Thyroid | PTC | 1.45e-12 | 3.52e-01 | 0.2044 |
5569 | PKIA | ATC13 | Human | Thyroid | ATC | 3.84e-09 | 1.85e-01 | 0.34 |
5569 | PKIA | ATC5 | Human | Thyroid | ATC | 6.46e-05 | 2.13e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Esophagus | ESCC | ![]() |
Skin | AK | ![]() |
Skin | SCCIS | ![]() |
Skin | cSCC | ![]() |
Thyroid | HT | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0072594112 | Thyroid | PTC | establishment of protein localization to organelle | 244/5968 | 422/18723 | 1.18e-28 | 4.97e-26 | 244 |
GO:0032386111 | Thyroid | PTC | regulation of intracellular transport | 202/5968 | 337/18723 | 1.12e-26 | 3.93e-24 | 202 |
GO:0033157112 | Thyroid | PTC | regulation of intracellular protein transport | 149/5968 | 229/18723 | 3.83e-25 | 1.15e-22 | 149 |
GO:0006913112 | Thyroid | PTC | nucleocytoplasmic transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:0051169112 | Thyroid | PTC | nuclear transport | 181/5968 | 301/18723 | 2.93e-24 | 7.69e-22 | 181 |
GO:0034504111 | Thyroid | PTC | protein localization to nucleus | 170/5968 | 290/18723 | 3.34e-21 | 6.38e-19 | 170 |
GO:004682223 | Thyroid | PTC | regulation of nucleocytoplasmic transport | 76/5968 | 106/18723 | 4.11e-17 | 3.70e-15 | 76 |
GO:0010563113 | Thyroid | PTC | negative regulation of phosphorus metabolic process | 219/5968 | 442/18723 | 4.47e-15 | 3.07e-13 | 219 |
GO:0045936113 | Thyroid | PTC | negative regulation of phosphate metabolic process | 218/5968 | 441/18723 | 7.08e-15 | 4.75e-13 | 218 |
GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
GO:1900180111 | Thyroid | PTC | regulation of protein localization to nucleus | 84/5968 | 136/18723 | 6.52e-13 | 3.08e-11 | 84 |
GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
GO:0051348113 | Thyroid | PTC | negative regulation of transferase activity | 137/5968 | 268/18723 | 3.78e-11 | 1.36e-09 | 137 |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:0017038111 | Thyroid | PTC | protein import | 109/5968 | 206/18723 | 2.74e-10 | 8.96e-09 | 109 |
GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
GO:0006469111 | Thyroid | PTC | negative regulation of protein kinase activity | 107/5968 | 212/18723 | 1.24e-08 | 2.96e-07 | 107 |
GO:005117017 | Thyroid | PTC | import into nucleus | 85/5968 | 159/18723 | 1.30e-08 | 3.08e-07 | 85 |
GO:0071900110 | Thyroid | PTC | regulation of protein serine/threonine kinase activity | 164/5968 | 359/18723 | 2.41e-08 | 5.43e-07 | 164 |
GO:000660616 | Thyroid | PTC | protein import into nucleus | 82/5968 | 155/18723 | 4.32e-08 | 9.27e-07 | 82 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PKIA | SNV | Missense_Mutation | c.7N>A | p.Asp3Asn | p.D3N | P61925 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PKIA | SNV | Missense_Mutation | c.196N>A | p.Glu66Lys | p.E66K | P61925 | protein_coding | tolerated(0.08) | possibly_damaging(0.554) | TCGA-MU-A51Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | c.182N>T | p.Thr61Ile | p.T61I | P61925 | protein_coding | deleterious(0.04) | benign(0.053) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | c.86C>T | p.Ser29Phe | p.S29F | P61925 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-AA-3684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | c.128N>A | p.Ala43Glu | p.A43E | P61925 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | rs536361273 | c.173N>A | p.Arg58Gln | p.R58Q | P61925 | protein_coding | tolerated(0.51) | benign(0.018) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PKIA | SNV | Missense_Mutation | novel | c.59N>T | p.Arg20Ile | p.R20I | P61925 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PKIA | SNV | Missense_Mutation | c.86C>T | p.Ser29Phe | p.S29F | P61925 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | c.86C>T | p.Ser29Phe | p.S29F | P61925 | protein_coding | deleterious(0) | possibly_damaging(0.825) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PKIA | SNV | Missense_Mutation | c.92N>T | p.Ala31Val | p.A31V | P61925 | protein_coding | deleterious(0.02) | benign(0.067) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |